Clover Health Investments Corporation
A Medicare Advantage insurer navigating margin pressure in a competitive healthcare market.
Published May 2, 2026 · Updated Nov 20, 2026 · by EllTec Analysis · Wave count: Lukas Köppl · ~22 min read · How to read this analysis →
Disclosure: the EllTec Analysis Tracking Portfolio currently holds no position in CLOV. (as of Nov 20, 2026)
For information and education only. Not investment advice. See the full disclaimer for details.
In 60 seconds
- Fundamentals
- Clover has moved from a cash-burning growth story to a profitable, fast-growing Medicare Advantage insurer: Q3 2026 revenue rose 53%, year to date GAAP net income is 62 m USD and guidance was raised.
- Strength
- Revenue +53% and Medicare Advantage membership of 158,907
- Risk
- Thin margins: small changes in medical costs can swing results, as the drop from Q2 to Q3 profit shows
- Premium
- The Elliott Wave part of this analysis is for subscribers: Risk Factors · Overall Assessment
Key figures
Interactive chartClover Health Investments CorporationNASDAQ:CLOV
Switch the time frame (minutes to months), zoom, scroll and draw your own lines. The chart is provided by TradingView. Loading it transfers data such as your IP address to TradingView. Your choice is remembered in this browser. Privacy policy
More analyses in Stocks
All stock analyses →
Pfizer Inc.
Pfizer at a decision point: is the multi-decade correction over, or does the patent cliff force one last low?

Volkswagen AG
Volkswagen is in a fundamentally weak phase with collapsing operating profit and falling deliveries in China, while the share trades at an extremely low valuation.

Alibaba Group
Alibaba is China's largest e-commerce and cloud group; the analysis covers its fundamentals, valuation, macro backdrop and the long-term wave structure.
New analyses by email
EllTec Analysis Updates: a short email whenever a new analysis is published or a scenario changes. Free, unsubscribe any time.
Newsletter →